HUE027443T2 - Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók - Google Patents

Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók Download PDF

Info

Publication number
HUE027443T2
HUE027443T2 HUE08830619A HUE08830619A HUE027443T2 HU E027443 T2 HUE027443 T2 HU E027443T2 HU E08830619 A HUE08830619 A HU E08830619A HU E08830619 A HUE08830619 A HU E08830619A HU E027443 T2 HUE027443 T2 HU E027443T2
Authority
HU
Hungary
Prior art keywords
cancer
stat3
cells
compound
tumor
Prior art date
Application number
HUE08830619A
Other languages
English (en)
Inventor
Chiang Jia Li
Zhiwei Jiang
Harry Rogoff
Youzhi Li
Jifeng Liu
Wei Li
Original Assignee
Boston Biomedical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Biomedical Inc filed Critical Boston Biomedical Inc
Publication of HUE027443T2 publication Critical patent/HUE027443T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/92—Naphthofurans; Hydrogenated naphthofurans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/74—Naphthothiophenes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)

Claims (4)

  1. készítmény, amely a következőkbe! -áll: f| vegyidet a következő csoportból választva: 2-acetik7-k!ór-n3ftöl2i3-blfurán-4,9'd$en; |-acet!í7-toí--na^ £«eetlHMrfto[23~ bjfurán-mg.-díon, :Μ^^12.3^Ιΐ0^η·»4^^#: löszförsav mm4H#&&oxa~n$MM~ tetrahidra'nafto[23-b]furá«^ői)-vWi| észter és foszförsav l-|4j-3fe5(ö-3%493a-tetrablcirx>-nafto[2,3-b]furán->2-i{}-vÍnÍífeter-ditr\ettlészter és ennek egy gyógyászatiiag elfogadható sója vagy szóivá^ és fii) egy kötőanyag, hordozó vagy oldószer, tumor-dsséif gátiásápan való felhasználásra olyan rak kezelésének esetén, amelynek ismerten vannak tumor-őssejtjei Is aberrált Stat3 útyönsImktMíása, olyan betegeknél., akiknek erre szükségük van, .ahol a kötőanyag, hordozó vagy oldószer a következőket tartalmazza:: lipkl a következő csoportból választva: tozfoiipid, szintetikus foszfefidii-koítn, tefmészétés foszfatidii-kolin, szfingomielin, semmid, foszfatidÜ-etanolemin, fosrfaüdil-glicerin, foszfadósav, koleszterin, koleszterin-szulfát, valamint haptén és poíietüeg-glikol (PEG) által konjogát fpdek intravénás adagoláshoz; vagy viaszos anyag a következő csoporfbél választve:: hiono-, dl- vágy fn-'gllééridóló 8 PEi mono- és di-zslrsa vészterel, PEéhgei: konjugáít g-vItatni « is ©eldcire: orális: adagoláshoz;: vagy a kötőanyag, hordozó vagy oldószer formája a kővetkező csoportból választott: miceíiáris emulzió,: szüszpenzié és nanorészecskés szuszpeozsé, továbbá tartalmaz még humán albumint Intravénás adagoláshoz, óz 1. igénypont szerinti felhasználású készítmény, ahol a készítmény a tumor-őssejt önmegújulását gátolja;. Az i. Igénypont szerinti felhasználású készítmény,: áhoka készítmény megöli éi tomon-össesiaket. Az 1, igénypont szerinti; felhasználásó vegyöfet ahol a rák fajtája a; kővetkező: csopcríhöi választott: emlődaganat, feji és nyak! daganat, tüdőrák, petefészefedaganat, hasnyálmirigy-daganat, kolorektális ksrcmőma, prosztatarák, melanoma, szarkoma, májdagaoat agydaganatok, myeloma multiplex és leukémia. Az l, Igénypont szerinti: felhasználású készítmény,. ahol; a rák metásztatskos. kemoterápiára vagy radfeterápiára: nem reagáló vagy a kezdeti kezelés után visszaeső. Az 1. igénypont szerinti felhasználású készítmény, alpi a rák a; következő csoportból; választott;: májdapnaí. feji és nyak! daganat, hasnyátalrlgy-tíagángt,: gypmorrék. yssérál, m*Mm, pfeelóma multiplex, metasztatikus emiőőageoat, ieakémla, limfóma, hyeíőcsőrafe agydaganat, giiőrna, hugyhólyagrák, endometriáiis daganat pajzsmlógyrák, epevezeíék-daganat, csontrák. skémrák IrétirmMasltbmal epeboíysgrék, ihifölskíspga^si;, -vastagbéldaganai, komrektáiis ^lamat, ^liiíri|^rá%: öír-garSí daganat, emlőrák, tüdőrák, prosztatarák, pet.##«^|k, risébnyffcráfc, melanoma és bőrrák:. ^ &&igénypont sxeríníí ifelhasanálásu késkftmány, ahol a rak kolöíéktiks rák, & & 6. igénypont szerinti ftelhasknálású készítmény, ahol a tik gyomorrak.: A $, Igé rsy:pí>nt »ÉI fáiba sznáiásct ü^ltmé hy, ahol a rák; nyéiocsősá k.
  2. 10. Az 1-S. igénypont bármelyike szsrmíi félhasznáiásó készítmény; aboí » M$ziímé«y· orális adagolasó ás napi négyszeri adagolásnál\-mm gyakoribb CQ.ID).
  3. 31. Az 1--6. Igénypont bármelyike szerinti felhasználású készítmény, ahol a készítményt l-'big/ro2 és kérölbélul 50 SÖÖ mg/mM^l közötti dózisban alkalmazzék.
  4. 12. Az 3 igénypont bármelyiké szerinti feidesználésu shot a Ms?ftm#nyl íö mg/nv és kör bibéiül §0 0(50 ?r5gymí £P0f közötti dózisban alkalmazzuk, 13 Az x, sgéeyppnt szerinti feihssznáíásó készítmény, ahol a vegyuiei 2meetrina0af2f3-b)fu;rán-á3· dión.
HUE08830619A 2007-09-10 2008-09-10 Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók HUE027443T2 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97114407P 2007-09-10 2007-09-10
US1337207P 2007-12-13 2007-12-13

Publications (1)

Publication Number Publication Date
HUE027443T2 true HUE027443T2 (hu) 2016-10-28

Family

ID=40452461

Family Applications (3)

Application Number Title Priority Date Filing Date
HUE08830619A HUE027443T2 (hu) 2007-09-10 2008-09-10 Stat3 útvonal gátlók újszerû csoportja és tumor-õssejt útvonal gátlók
HUE08830633A HUE029111T2 (hu) 2007-09-10 2008-09-10 Rák kezelését célzó új készítmények és módszerek
HUE08830471A HUE027657T2 (hu) 2007-09-10 2008-09-10 Új STAT3 útvonal inhibitorok és rák-õssejt inhibitorok

Family Applications After (2)

Application Number Title Priority Date Filing Date
HUE08830633A HUE029111T2 (hu) 2007-09-10 2008-09-10 Rák kezelését célzó új készítmények és módszerek
HUE08830471A HUE027657T2 (hu) 2007-09-10 2008-09-10 Új STAT3 útvonal inhibitorok és rák-õssejt inhibitorok

Country Status (15)

Country Link
US (12) US9732055B2 (hu)
EP (6) EP3058941B1 (hu)
JP (16) JP5688840B2 (hu)
CN (6) CN104586832B (hu)
CA (4) CA2736532C (hu)
CY (3) CY1117604T1 (hu)
DK (4) DK2190429T3 (hu)
ES (3) ES2584904T3 (hu)
HK (3) HK1148906A1 (hu)
HR (3) HRP20160430T1 (hu)
HU (3) HUE027443T2 (hu)
PL (4) PL2200431T3 (hu)
PT (2) PT2194987T (hu)
SI (3) SI2194987T1 (hu)
WO (3) WO2009036059A2 (hu)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101155579B (zh) 2005-02-03 2012-10-31 综合医院公司 治疗吉非替尼耐药性癌症的方法
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
US9732055B2 (en) * 2007-09-10 2017-08-15 Boston Biomedical, Inc. Compositions and methods for cancer treatment
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
US20130331294A1 (en) 2007-11-09 2013-12-12 Fox Chase Cancer Center Egfr/nedd9/tgf-beta interactome and methods of use thereof for the identification of agents having efficacy in the treatment of hyperproliferative disorders
WO2009062199A1 (en) * 2007-11-09 2009-05-14 Fox Chase Cancer Center EGFR/NEDD9/TGF-β LNTERACTOME AND METHODS OF USE THEREOF FOR THE IDENTIFICATION OF AGENTS HAVING EFFICACY IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
KR20130088908A (ko) 2008-06-17 2013-08-08 와이어쓰 엘엘씨 Ｈｋｉ-272 및 비노렐빈을 함유하는 항신생물성 조합물
EA020766B1 (ru) 2008-07-08 2015-01-30 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Ингибиторы пролиферации и активации переносчика сигнала и активатора транскрипции (stats)
CN109464445A (zh) 2008-08-04 2019-03-15 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
EP2370082A4 (en) * 2008-12-01 2012-05-30 Univ Central Florida Res Found FOR BELLY CANCER CELLS CYTOTOXIC DRUG COMPOSITION
ES2941894T3 (es) 2009-04-06 2023-05-26 Wyeth Llc Régimen de tratamiento que utiliza neratinib contra el cáncer de mama
CN101897979B (zh) * 2009-05-27 2012-08-22 上海市计划生育科学研究所 治疗前列腺疾病的靶向药物
WO2011069141A2 (en) 2009-12-04 2011-06-09 Board Of Regents, The University Of Texas System Interferon therapies in combination with blockade of stat3 activation
PL2520575T3 (pl) * 2009-12-28 2017-05-31 General Incorporated Association Pharma Valley Project Supporting Organization Związek 1,3,4-oksadiazolo-2-karboksyamidowy
US20110275577A1 (en) * 2010-01-08 2011-11-10 Moleculin, Llc Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs
KR101821343B1 (ko) 2010-03-01 2018-01-23 타우 쎄라퓨틱스 엘엘씨 암 진단 및 영상화
AU2015218436B9 (en) * 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
CA2793526C (en) * 2010-03-19 2018-05-01 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells
DK2547205T3 (da) * 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
CA2959931A1 (en) * 2010-03-19 2011-09-22 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells
WO2011130677A1 (en) * 2010-04-16 2011-10-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Inhibitors of cancer stem cells
US20110301194A1 (en) * 2010-06-02 2011-12-08 Arqule, Inc. Method for Determining Treatment Efficacy
WO2012024818A1 (en) * 2010-08-24 2012-03-01 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. Novel anphthoquinones for disease therapies
WO2012036214A1 (ja) * 2010-09-16 2012-03-22 国立大学法人大阪大学 自己免疫疾患、炎症性疾患、アレルギー性疾患、臓器移植に伴う症状の治療薬および予防薬
US20130252956A1 (en) * 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
CA2812348A1 (en) * 2010-11-30 2012-06-07 London Health Sciences Centre Research Inc. Egfr antagonist for the treatment of heart disease
WO2012078982A2 (en) * 2010-12-09 2012-06-14 The Ohio State University Xzh-5 inhibits constitutive and interleukin-6-induced stat3 phosphorylation in human hepatocellular carcinoma cells
CN103402993A (zh) * 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
CN103717214A (zh) * 2011-06-06 2014-04-09 阿克比治疗有限公司 用于稳定低氧诱导因子-2α作为治疗癌症的方法的化合物和组合物
EP2755674A4 (en) * 2011-09-12 2015-04-08 Tau Therapeutics Llc ANTAGONISTS OF PRODUCTS OF THE HS-459642-UNIGEN CLUSTER TO AVOID PROLIFERATION, DEVELOPMENT, OR DIFFERENTIATION OF STEM CELLS WITH CANCER STEM CELLS
US20150184246A1 (en) * 2011-11-11 2015-07-02 Millennium Pharmaceuticals, Inc. Biomarkers of response to proteasome inhibitors
WO2013120229A1 (en) * 2012-02-17 2013-08-22 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. METHOD FOR PREPARING AQUEOUS MANO PARTICLE SUSPENSIONS OF DERIVATIVES OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURAN ALIPHATIC ACID ESTERS
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013166618A1 (en) * 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
MX367055B (es) 2012-06-26 2019-08-02 Del Mar Pharmaceuticals El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa.
CN106421795A (zh) * 2012-10-08 2017-02-22 贾力 预防原发性肿瘤在手术切除后再转移的药用组合物
DE102013003107A1 (de) 2013-02-25 2014-09-11 Thomas Rühl Naphthofurandione mit einer 1-Bromalkylgruppe oder einer 1-Hydroxyalkylgruppe in 2-Position und einer Alkylgruppe in 3-Position zum Furanring-Sauerstoff und Verfahren zu deren Herstellung
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
RU2015147696A (ru) 2013-04-09 2017-05-12 Бостон Байомедикал, Инк. Способы лечения злокачественной опухоли
ES2728305T3 (es) * 2013-04-29 2019-10-23 Ogd2 Pharma Uso como diana del gangliosido GD2 O-acetilado como una nueva estrategia terapéutica y de diagnóstico para cáncer de células madre cancerosas
US10745489B2 (en) 2013-04-29 2020-08-18 Ogd2 Pharma Targeting o-acetylated gd2 ganglioside as a new therapeutic and diagnostic strategy for Cancer Stem Cells cancer
JP6466924B2 (ja) 2013-10-04 2019-02-06 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環式化合物及びその使用
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP6472096B2 (ja) * 2014-01-27 2019-02-20 ボストン バイオメディカル， インコーポレイテッド 癌を処置するための新規方法
JP6695275B2 (ja) * 2014-02-07 2020-05-20 ボストン バイオメディカル， インコーポレイテッド ３−置換カルボニル−ナフト［２，３−ｂ］フラン誘導体又はその薬学的に許容される塩
US11406707B2 (en) 2014-02-10 2022-08-09 H. Lee Moffitt Cancer Center And Research Institute, Inc. STAT3 phosphorylation during graft-versus-host disease
DK3119397T3 (da) 2014-03-19 2022-03-28 Infinity Pharmaceuticals Inc Heterocykliske forbindelser til anvendelse i behandling af PI3K-gamma-medierede lidelser
US11230719B2 (en) * 2014-03-26 2022-01-25 Denovo Biopharma Llc Retroviral vector having immune-stimulating activity
WO2015164870A1 (en) 2014-04-25 2015-10-29 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gamma-aa-peptide stat3/dna inhibitors and methods of use
US20170266182A1 (en) * 2014-05-09 2017-09-21 The Brigham And Women's Hospital, Inc. Treatment of IgG-Immune Complex-Mediated Organ Damage
DK3153508T3 (da) * 2014-06-09 2020-05-18 Kyoto Pharma Ind Naphthofuranderivater til anvendelse som anticancermidler
CN107072984B (zh) * 2014-07-15 2021-10-01 约翰·霍普金斯大学 源自骨髓的抑制细胞的抑制和免疫检查点阻断
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
KR20160066490A (ko) * 2014-12-02 2016-06-10 주식회사 씨앤드씨신약연구소 헤테로사이클 유도체 및 그의 용도
CN107635991B (zh) 2015-01-08 2021-01-01 美国政府健康及人类服务部 作为tdp2的抑制剂的呋喃并喹啉二酮
JP6630364B2 (ja) 2015-03-27 2020-01-15 ボストン バイオメディカル， インコーポレイテッド 水溶性プロドラッグ
CN104725480A (zh) * 2015-04-06 2015-06-24 苏州普罗达生物科技有限公司 一种信号传导及转录激活因子抑制多肽及其应用
CN104693279A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 关于信号传导及转录激活因子抑制多肽及其应用
CN104693280A (zh) * 2015-04-06 2015-06-10 苏州普罗达生物科技有限公司 信号传导及转录激活因子抑制多肽及其应用
WO2016168858A1 (en) * 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
TW201713328A (zh) * 2015-04-17 2017-04-16 波士頓生醫公司 治療癌症之方法
CA2983010A1 (en) * 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
JP2018514557A (ja) 2015-04-27 2018-06-07 ボストン バイオメディカル， インコーポレイテッド Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
HUE038541T2 (hu) * 2015-05-14 2018-10-29 NuCana plc Rák kezelési módszerek
JP6949726B2 (ja) * 2015-05-15 2021-10-13 ノバルティス アーゲー Ｅｇｆｒ変異癌を治療する方法
AU2016271475A1 (en) 2015-06-03 2017-12-21 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
US10329267B2 (en) * 2015-07-17 2019-06-25 Sumitomo Dainippon Pharma Co., Ltd. Method for producing 2-acetyl-4H,9H-naphtho[2,3-b]furan-4,9-dione
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
WO2017023866A1 (en) * 2015-07-31 2017-02-09 Boston Biomedical, Inc. Method of targeting stat3 and other non-druggable proteins
KR20180058741A (ko) 2015-09-14 2018-06-01 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
JP7038653B2 (ja) 2015-10-05 2022-03-18 ニューカナ パブリック リミテッド カンパニー 併用療法
EP3400070A4 (en) * 2016-01-07 2019-07-03 Virginia Commonwealth University METHOD FOR MODULATING SURVIVAL AND STRAIN CHARACTER OF CANCER CELLS WITH MDA-9 / SYNTENIN (SDCBP)
US20190076392A1 (en) 2016-01-20 2019-03-14 Boston Biomedical, Inc. Methods for treating cancer
CN109104862A (zh) * 2016-03-01 2018-12-28 中央研究院 4,9-二氧代-4,9-二氢萘并[2,3-b]呋喃-3-羧酰胺衍生物及其用于治疗增生性疾病与感染性疾病的用途
US11946927B2 (en) 2016-03-14 2024-04-02 Musidora Biotechnology Llc Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment
US10295527B2 (en) 2016-03-14 2019-05-21 Bruce Yacyshyn Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10738023B2 (en) 2016-03-25 2020-08-11 Sumitomo Dainippon Pharma Co., Ltd. Method for producing 2-alkylcarbonylnaphtho[2,3-b]furan-4,9-dione-related substance, and said related substance
JP2017171640A (ja) * 2016-03-25 2017-09-28 学校法人兵庫医科大学 癌の治療システム
CN105837541A (zh) * 2016-04-23 2016-08-10 何淑琼 磷酸苯丙哌林的药物组合物及其在生物医药中的应用
CN105906595A (zh) * 2016-04-23 2016-08-31 陈斌 丙酸倍氯米松的药物组合物及其在生物医药中的应用
GB201609600D0 (en) 2016-06-01 2016-07-13 Nucuna Biomed Ltd Cancer treatments
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3029596A1 (en) 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
CN106380456B (zh) * 2016-08-29 2019-03-26 中南大学 一种合成苯并呋喃萘醌衍生物的方法
WO2018096401A1 (en) 2016-11-22 2018-05-31 Hitoshi Ban New naphtho[2,3-b]furan derivatives
WO2018098352A2 (en) 2016-11-22 2018-05-31 Jun Oishi Targeting kras induced immune checkpoint expression
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
KR20190089191A (ko) * 2016-11-30 2019-07-30 타임, 인크. 티로신 유도체 및 이들을 포함하는 조성물
CN108778275A (zh) * 2017-01-22 2018-11-09 江苏恒瑞医药股份有限公司 Egfr/her2抑制剂联合嘧啶类抗代谢药物的用途
WO2018183908A1 (en) * 2017-03-31 2018-10-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating ovarian tumors
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CA3066054A1 (en) * 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
EP3654841B1 (en) * 2017-07-20 2024-02-07 Board Of Supervisors Of Louisiana State University Targeted osmotic lysis of malignant cancer cells using pulsed magnetic field gradients
EP3686182A4 (en) 2017-09-22 2021-06-09 Sumitomo Dainippon Pharma Co., Ltd. CHEMICALLY ACTIVATED WATER-SOLUBLE PRODRUG
CN111479584A (zh) * 2017-11-16 2020-07-31 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂和抗pd-1/pd-l1抗体的组合
EP3501511A1 (en) * 2017-12-22 2019-06-26 Fundación Centro Nacional De Investigaciones Oncológicas Carlos III Means for preventing and treating brain metastasis
EP3733840A4 (en) * 2017-12-28 2021-11-24 Kaneka Corporation INHIBITOR OF PLURIPOTENT STEM CELL AGGREGATION
CN107973788B (zh) * 2018-01-09 2021-07-09 沈阳药科大学 Bbi608衍生物及其制备与用途
BR112020017481A8 (pt) * 2018-03-20 2022-12-06 Sumitomo Dainippon Pharma Co Ltd Derivados de di-hidrocromeno
JP7411315B2 (ja) * 2018-04-19 2024-01-11 トゥヴァルディ セラピューティクス，インク． Ｓｔａｔ３阻害剤
WO2019232214A1 (en) 2018-05-31 2019-12-05 Boston Biomedical, Inc. Methods of using napabucasin
CA3113408A1 (en) * 2018-09-18 2020-03-26 Kabushiki Kaisha Yakult Honsha Cancer combination therapy using quinoline carboxamide derivative
EP3865130A4 (en) * 2018-10-12 2022-07-20 1Globe Biomedical Co., Ltd. NEW COMBINATION SOLUTION FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT CANCER
CN109288846A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat3抑制剂晶型a联合用药物组合物
CN109288845A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种咔唑类stat抑制剂马来酸盐晶型ii联合用药物组合物及其制备方法
CN109288847A (zh) * 2018-10-31 2019-02-01 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂甲磺酸盐晶型p联合用药物组合物
CN109200044A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂酒石酸盐联合用药物组合物
CN109172563A (zh) * 2018-10-31 2019-01-11 南京先进生物材料与过程装备研究院有限公司 一种噻吨酮类紫杉醇和stat3抑制剂联合用药物组合物
CN109331004A (zh) * 2018-10-31 2019-02-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和二苯并[b,d]噻吩类STAT抑制剂甲磺酸盐A晶型联合用药物组合物
CN109966297A (zh) * 2018-10-31 2019-07-05 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和咔唑类stat抑制剂马来酸盐晶型i联合用药物组合物
CN109200052A (zh) * 2018-10-31 2019-01-15 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴酮类stat3抑制剂联合用药物组合物
CN109846888A (zh) * 2018-10-31 2019-06-07 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和吲哚类stat3抑制剂联合用药物组合物
CN109223758A (zh) * 2018-10-31 2019-01-18 南京先进生物材料与过程装备研究院有限公司 一种紫杉醇和芴类stat3抑制剂联合用药物组合物
CN109364252B (zh) * 2018-11-21 2021-09-28 南京大学 抑制ifn-i至arg1诱导通路在制备抗肿瘤药物组合物中的应用
JP2022528481A (ja) * 2019-04-09 2022-06-10 ジェネラス バイオファーマ リミテッド ピモジドとメトトレキサートの医薬組成物、及びその使用
US11564913B2 (en) * 2019-05-03 2023-01-31 Children's Hospital Medical Center Compositions and methods for treating cancer
CN110218198B (zh) * 2019-05-22 2022-06-28 广州中医药大学(广州中医药研究院) 一种萘醌并三氮唑核心骨架衍生物化合物及其制备方法和应用
JPWO2020251015A1 (hu) * 2019-06-14 2020-12-17
JP7287929B2 (ja) * 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬
CN114761006A (zh) * 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
US20230026808A1 (en) * 2019-11-20 2023-01-26 Yale University Compounds, compositions, and methods for treating ischemia-reperfusion injury and/or lung injury
US20230013636A1 (en) * 2019-12-05 2023-01-19 Board Of Regents, The University Of Texas System Exosomes-based therapy for liver fibrosis and other diseases with fibrosis
WO2021185234A1 (zh) * 2020-03-16 2021-09-23 正大天晴药业集团股份有限公司 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
JP2023525767A (ja) * 2020-05-11 2023-06-19 パーデュー・リサーチ・ファウンデーション 連続フロー条件下でのロムスチンのスケールアップ合成
CN114286684B (zh) * 2020-07-27 2024-01-05 华中科技大学 与stat3相关的疾病的预防和/或治疗
WO2022216930A1 (en) * 2021-04-08 2022-10-13 Virginia Commonwealth University Novel mda-9 antagonist with anti-metastatic potential
CN114591306B (zh) * 2022-03-03 2024-03-01 陕西中医药大学 一种1,2,4-三唑环的1,4萘醌类stat3抑制剂及其应用

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2472133A (en) * 1947-03-20 1949-06-07 Du Pont Thiophanthraquinone derivatives
SU1049490A1 (ru) 1982-05-18 1983-10-23 Ордена Трудового Красного Знамени Институт Химии Ан Мсср (3 @ ,9 @ ,9 @ )-6,6,9 @ -Триметилтранспергидронафто(2,1- @ )фуран,в качестве душистого компонента парфюмерной композиции
JPS616149A (ja) 1984-06-20 1986-01-11 Mitsubishi Electric Corp 無機絶縁体の製法
JPS63196576A (ja) * 1987-02-10 1988-08-15 Tetsuo Ikegawa フラルナフトキノン誘導体と制癌剤及びその製造方法
EP0309926A3 (de) 1987-09-29 1990-12-05 Siemens Aktiengesellschaft Verfahren zur Herstellung vollparametrisierbarer Schaltungen in integrierter Schaltkreistechnik
JPH01121284A (ja) 1987-11-06 1989-05-12 Eisai Co Ltd トコフェロール　ｎ，ｎ−ジアルキルアミノアルキルカルボン酸エステルの胆汁酸塩
EP0402192A1 (fr) 1989-05-31 1990-12-12 BODET, Jean Augustin Article en carton ou matière analogue et procédé de fabrication
JPH04139177A (ja) 1989-12-28 1992-05-13 Dainippon Ink & Chem Inc フラルベンゾキノン誘導体及びその製造方法並びに制癌剤
JP2942015B2 (ja) * 1990-07-10 1999-08-30 キヤノン株式会社 電子写真感光体およびそれを用いた電子写真装置
EP0757293B1 (en) * 1990-07-10 1999-12-22 Canon Kabushiki Kaisha Electrophotographic photosensitive member
TW252136B (hu) 1992-10-08 1995-07-21 Ciba Geigy
JP3598168B2 (ja) 1996-03-18 2004-12-08 独立行政法人 科学技術振興機構 抗ウイルス剤
JPH1121284A (ja) 1997-06-30 1999-01-26 Kotobuki:Kk フラノナフトキノン誘導体及びこれを含有する医薬
JPH1165141A (ja) * 1997-08-11 1999-03-05 Canon Inc 電子写真感光体、該電子写真感光体を有するプロセスカ−トリッジ及び電子写真装置
US6174913B1 (en) 1998-06-05 2001-01-16 The University Of North Carolina At Chapel Hill Naphtho- and dihydrobenzo-thiophene derivatives as cytotoxic antitumor agents
EP1146869A2 (en) 1999-01-27 2001-10-24 University Of South Florida Inhibition of stat3 signal transduction for human cancer therapy
DK2266537T3 (en) 1999-04-01 2014-12-15 Talon Therapeutics Inc Compositions for treating cancer
US6482943B1 (en) 1999-04-30 2002-11-19 Slil Biomedical Corporation Quinones as disease therapies
AU772551B2 (en) * 1999-08-02 2004-04-29 F. Hoffmann-La Roche Ag New selective retinoid agonists
JP2001097860A (ja) * 1999-09-29 2001-04-10 Japan Science & Technology Corp 抗薬剤耐性菌剤と抗クラミジア剤
UA75055C2 (uk) * 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
KR20010100194A (ko) * 2000-03-13 2001-11-14 박호군 여러 가지 물질의 가용화용 조성물과 제형 및 그들의제조방법
US7998947B2 (en) 2001-03-28 2011-08-16 University Of South Florida Materials and methods for treatment of cancer and identification of anti-cancer compounds
GB0117696D0 (en) 2001-07-20 2001-09-12 Bradford Particle Design Plc Particle information
US20040092428A1 (en) 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
CA2468197A1 (en) 2001-11-29 2003-06-05 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
EP1487436A4 (en) * 2002-03-08 2009-06-03 Signal Pharm Inc POLYTHERAPY FOR TREATING, PREVENTING OR MANAGING PROLIFERATIVE DISORDERS AND CANCERS
ATE337014T1 (de) 2002-03-15 2006-09-15 Natimmune As Mannose-bindungsprotein enthaltende pharmazeutische zusammensetzungen
WO2004024145A1 (en) 2002-09-10 2004-03-25 Dabur Research Foundation Anti-cancer activity of carvedilol and its isomers
US20060142271A1 (en) 2002-09-17 2006-06-29 Klaus Muller Novel lapacho compounds and methods of use thereof
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
TWI335913B (en) 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
IS6633A (is) 2002-11-22 2004-05-23 Omega Farma Ehf. Samsetningar af fínasteríð töflum
EP2481814A3 (en) * 2003-06-09 2012-10-10 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
CA2535584A1 (en) 2003-08-13 2005-02-24 University Of South Florida Platinum complexes for the treatment of tumors
US20050049207A1 (en) * 2003-09-03 2005-03-03 Kaufmann Doug A. Method of treating and preventing cancer
WO2005033048A2 (en) * 2003-09-29 2005-04-14 The Johns Hopkins University Wnt pathway antagonists
UA83272C2 (uk) 2003-12-02 2008-06-25 Клевеленд Клінік Фаундейшн Спосіб захисту від ефектів іонізуючого випромінювання за допомогою флагеліну
CN102603565A (zh) * 2003-12-11 2012-07-25 得克萨斯州大学系统董事会 治疗细胞增殖疾病的化合物
DE10359828A1 (de) * 2003-12-12 2005-07-28 Zoser B. Dr.Rer.Nat. Salama CHP-Gemcitabin- Kombinationsmittel und ihre Verwendung als Antitumorwirkstoffe, insbesondere Antimetastasierungswirkstoffe
US20060030536A1 (en) 2004-04-09 2006-02-09 University Of South Florida Combination therapies for cancer and proliferative angiopathies
JP2004224802A (ja) * 2004-04-21 2004-08-12 Japan Science & Technology Agency 抗菌剤
AU2005270102A1 (en) * 2004-07-02 2006-02-09 Icos Corporation Compounds useful for inhibiting Chk1
JP2008509976A (ja) * 2004-08-18 2008-04-03 アストラゼネカ アクチボラグ 選択された縮合複素環及びその使用
MX2007005434A (es) * 2004-11-08 2007-07-10 Baxter Int Composiciones de nanoparticulado de inhibidor de tubulina.
WO2006056399A2 (en) 2004-11-24 2006-06-01 Novartis Ag Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors
US7807662B2 (en) * 2004-12-23 2010-10-05 University Of South Florida Platinum IV complex inhibitor
AU2006216510A1 (en) * 2005-02-25 2006-08-31 The Regent Of The University Of Michigan Small molecule inhibitors of STAT3 and the uses thereof
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
JP2006290871A (ja) * 2005-03-16 2006-10-26 Taheebo Japan Kk 抗癌性を示す化合物およびその中間体ならびにそれらの製造方法
US20060252073A1 (en) * 2005-04-18 2006-11-09 Regents Of The University Of Michigan Compositions and methods for the treatment of cancer
WO2006126505A1 (ja) 2005-05-26 2006-11-30 The University Of Tokyo Stat機能阻害剤およびその応用
WO2007013946A2 (en) * 2005-07-20 2007-02-01 University Of South Florida Method of predicting responsiveness to chemotherapy and selecting treatments
EP1945612A2 (en) 2005-10-13 2008-07-23 Orchid Research Laboratories Limited Heterocyclic compounds as pstat3/il-6 inhibitors
UA96139C2 (uk) * 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
JP2007145680A (ja) 2005-11-30 2007-06-14 Idemitsu Kosan Co Ltd 水素発生材料および水素発生方法
BRPI0620624A2 (pt) * 2005-12-24 2011-11-16 Biotica Tech Ltd análogo de 21-deóximacbecina ou um sal farmaceuticamente aceitável do mesmo, método para a produção do mesmo, composição farmacêutica, cepas hospedeira e engenheirada, e, uso das mesmas
US20090012075A1 (en) * 2006-01-12 2009-01-08 Miller Thomas A Fluorinated Arylamide Derivatives
KR20140093764A (ko) * 2006-02-09 2014-07-28 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
US20070243192A1 (en) * 2006-02-21 2007-10-18 Regents Of The University Of Michigan Growth hormone receptor antagonist cancer treatment
AU2007218966A1 (en) * 2006-02-24 2007-08-30 Merck Frosst Canada Ltd. 2-(phenyl or heterocyclic) - 1h-phenanthro [9,10-d] imidazoles
RU2456265C2 (ru) 2006-03-31 2012-07-20 Дзе Борд Оф Риджентс Оф Дзе Юниверсити Оф Техас Систем Биологически доступная для перорального применения кофейная кислота, относящаяся к противоопухолевым лекарственным средствам
US20070238770A1 (en) 2006-04-05 2007-10-11 Bristol-Myers Squibb Company Process for preparing novel crystalline forms of peliglitazar, novel stable forms produced therein and formulations
US8828451B2 (en) 2006-10-04 2014-09-09 University Of South Florida Akt sensitization of cancer cells
WO2008077062A2 (en) * 2006-12-19 2008-06-26 Board Of Regents, The University Of Texas System Suppression of stat3 reactivation after src kinase inhibition to treat cancer
JP4077863B1 (ja) 2007-05-31 2008-04-23 タヒボジャパン株式会社 抗癌活性を有する光学活性２−（１−ヒドロキシエチル）−５−ヒドロキシナフト［２，３−ｂ］フラン−４，９−ジオンの製法
US9732055B2 (en) 2007-09-10 2017-08-15 Boston Biomedical, Inc. Compositions and methods for cancer treatment
US20100298402A1 (en) 2007-11-06 2010-11-25 Orchid Research Laboratories Limited Stilbene derivatives as pstat3/il-6 inhibitors
CA2793526C (en) 2010-03-19 2018-05-01 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells
DK2547205T3 (da) 2010-03-19 2024-05-27 1Globe Biomedical Co Ltd Hidtil ukendte fremgangsmåder til målretning mod cancerstamceller
AU2015218436B9 (en) 2010-03-19 2017-03-09 Boston Biomedical, Inc. Novel Methods For Targeting Cancer Stem Cells
CA2959931A1 (en) 2010-03-19 2011-09-22 Boston Biomedical, Inc. Naphthofuran compounds and compositions for targeting cancer stem cells
CN103402993A (zh) 2011-03-04 2013-11-20 舟山海中洲新生药业有限公司 用于疾病治疗的4，9-二羟基-萘并[2,3-b] 呋喃新型酯
US8977803B2 (en) 2011-11-21 2015-03-10 Western Digital Technologies, Inc. Disk drive data caching using a multi-tiered memory
WO2013166618A1 (en) 2012-05-08 2013-11-14 Zhoushan Haizhongzhou Xinsheng Pharmaceuticals Co., Ltd. PRODRUGS OF 4,9-DIHYDROXY-NAPHTHO[2,3-b]FURANS FOR CIRCUMVENTING CANCER MULTIDRUG RESISTANCE
RU2015147696A (ru) 2013-04-09 2017-05-12 Бостон Байомедикал, Инк. Способы лечения злокачественной опухоли
CA2983010A1 (en) 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
TW201713328A (zh) 2015-04-17 2017-04-16 波士頓生醫公司 治療癌症之方法
WO2016168858A1 (en) 2015-04-17 2016-10-20 Boston Biomedical, Inc. Methods for treating cancer
JP2018514557A (ja) 2015-04-27 2018-06-07 ボストン バイオメディカル， インコーポレイテッド Ｓｔａｔ３経路阻害薬およびキナーゼ阻害薬を用いて癌を治療するための方法
AU2016271475A1 (en) 2015-06-03 2017-12-21 Boston Biomedical, Inc. Compositions comprising a cancer stemness inhibitor and an immunotherapeutic agent for use in treating cancer
US20190076392A1 (en) 2016-01-20 2019-03-14 Boston Biomedical, Inc. Methods for treating cancer
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer

Also Published As

Publication number Publication date
EP2190429B1 (en) 2016-04-20
DK2190429T3 (en) 2016-05-30
US9745278B2 (en) 2017-08-29
US20180030022A1 (en) 2018-02-01
EP2194987A2 (en) 2010-06-16
JP2016065101A (ja) 2016-04-28
CN101854802B (zh) 2014-12-03
DK3050566T3 (en) 2019-03-11
CY1118476T1 (el) 2017-07-12
EP2200431A4 (en) 2011-12-21
ES2569215T3 (es) 2016-05-09
HRP20160625T1 (hr) 2016-08-12
US20210115006A1 (en) 2021-04-22
EP3058941B1 (en) 2019-05-22
EP3067054B1 (en) 2020-12-30
US20120252763A1 (en) 2012-10-04
US20170197932A1 (en) 2017-07-13
US20150018410A1 (en) 2015-01-15
PL3067054T3 (pl) 2021-10-04
CN105963289A (zh) 2016-09-28
JP2010539095A (ja) 2010-12-16
JP2020143135A (ja) 2020-09-10
CA2736532A1 (en) 2009-03-19
JP5872160B2 (ja) 2016-03-01
HK1148942A1 (zh) 2011-09-23
CN101854802A (zh) 2010-10-06
DK2194987T3 (en) 2016-08-15
PL2190429T3 (pl) 2016-09-30
CN101854930B (zh) 2016-05-04
US20100310503A1 (en) 2010-12-09
CN103288787B (zh) 2016-08-03
HUE027657T2 (hu) 2016-11-28
US20200039948A1 (en) 2020-02-06
CA2736564A1 (en) 2009-03-19
JP2015034179A (ja) 2015-02-19
SI2194987T1 (sl) 2016-10-28
JP5938072B2 (ja) 2016-06-22
JP2016034976A (ja) 2016-03-17
EP2194987A4 (en) 2011-11-30
HK1148906A1 (en) 2011-09-23
CA2736563A1 (en) 2009-03-19
CA2736563C (en) 2016-01-26
EP3050566A3 (en) 2016-11-30
EP3050566A2 (en) 2016-08-03
US10851075B2 (en) 2020-12-01
EP3050566B1 (en) 2018-11-28
HK1148943A1 (en) 2011-09-23
JP2010539097A (ja) 2010-12-16
JP2016147906A (ja) 2016-08-18
HRP20160430T1 (hr) 2016-05-20
CN104586832A (zh) 2015-05-06
CN101854937A (zh) 2010-10-06
PL2194987T3 (pl) 2017-01-31
JP2010539098A (ja) 2010-12-16
CA2911990C (en) 2018-03-20
ES2584904T3 (es) 2016-09-30
EP2190429A1 (en) 2010-06-02
WO2009036059A2 (en) 2009-03-19
JP2018131464A (ja) 2018-08-23
JP2015038151A (ja) 2015-02-26
JP6346628B2 (ja) 2018-06-20
HRP20160949T1 (hr) 2016-10-07
JP2019073560A (ja) 2019-05-16
US20110112180A1 (en) 2011-05-12
US9732055B2 (en) 2017-08-15
JP5701603B2 (ja) 2015-04-15
CA2911990A1 (en) 2009-03-19
PT2200431T (pt) 2016-08-03
JP5925849B2 (ja) 2016-05-25
JP6358659B2 (ja) 2018-07-18
SI2200431T1 (sl) 2016-10-28
WO2009036099A1 (en) 2009-03-19
EP2190429A4 (en) 2011-12-14
DK2200431T3 (en) 2016-08-15
CN101854930A (zh) 2010-10-06
US9834532B2 (en) 2017-12-05
JP2018076349A (ja) 2018-05-17
CA2736532C (en) 2018-03-20
CN105963289B (zh) 2021-02-26
EP3058941A1 (en) 2016-08-24
JP2014221843A (ja) 2014-11-27
US10377731B2 (en) 2019-08-13
PL2200431T3 (pl) 2017-01-31
ES2583010T3 (es) 2016-09-16
US20190135773A1 (en) 2019-05-09
EP2200431B1 (en) 2016-07-20
HUE029111T2 (hu) 2017-02-28
US20210024482A1 (en) 2021-01-28
CY1117833T1 (el) 2017-05-17
JP6106149B2 (ja) 2017-03-29
CN101854937B (zh) 2013-03-27
EP2200431A1 (en) 2010-06-30
EP3067054A1 (en) 2016-09-14
JP2014231522A (ja) 2014-12-11
JP2020117547A (ja) 2020-08-06
US20180030021A1 (en) 2018-02-01
CN103288787A (zh) 2013-09-11
CY1117604T1 (el) 2017-04-26
WO2009036101A1 (en) 2009-03-19
SI2190429T1 (sl) 2016-10-28
EP2194987B1 (en) 2016-05-18
JP5688840B2 (ja) 2015-03-25
PT2194987T (pt) 2016-08-05
WO2009036059A3 (en) 2009-07-02
US20190263768A1 (en) 2019-08-29
JP6347795B2 (ja) 2018-06-27
CN104586832B (zh) 2018-02-16
US8877803B2 (en) 2014-11-04
JP2016094465A (ja) 2016-05-26

Similar Documents

Publication Publication Date Title
US20210024482A1 (en) Novel Group of STAT3 Pathway Inhibitors and Cancer Stem Cell Pathway Inhibitors
JP2010539097A5 (hu)
ES2713455T3 (es) Un grupo novedoso de inhibidores de la ruta STAT3 e inhibidores de la ruta de células madre de cáncer